Trelegy Ellipta 100 μg/ 62,5 μg/ 25 μg Powder for Inhalation
PDF Leaflet Revision Date: 11 April 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Maintenance treatment for COPD in adults.
Dosage (summary)
One inhalation once daily for adults; no adjustment for elderly or renal/hepatic impairment.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety not established; potential risks in pregnancy and breastfeeding.
Key Drug Interactions
- Beta-blockers may reduce effectiveness
- CYP3A4 inhibitors may increase exposure
Contraindications
- Severe milk-protein allergy
- Hypersensitivity to components
Common side effects
- Pneumonia
- Upper respiratory tract infection
- Headache
- Cough
Counselling Points
- Rinse mouth after use
- Do not exceed recommended dose
- Monitor for pneumonia symptoms
Serious warnings
- Not for acute symptom relief
- Paradoxical bronchospasm
- Cardiovascular effects
Important Disclaimer
The Trelegy Ellipta 100 μg/ 62,5 μg/ 25 μg Powder for Inhalation professional information leaflet below is the property of Glaxosmithkline South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
